Navigation Links
Lotus Clinical Research Executive to Present on Opioid Sparing Endpoints at 11th Annual Pain & Migraine Therapeutics Summit
Date:8/22/2017

One of the biggest opportunities to reduce the dependency on opioids in pain management is the practice of opioid-dose sparing. Opioid-dose sparing refers to the reduction of opioid dosage by combining with a non-opioid. This practice has shown promising results, including with non-steroidal anti-inflammatory drugs (NSAIDs).

The potential for new therapies to replace opioids and/or reduce dosages, however, is limited by the success of clinical trials and the utilization of effective endpoints for judging efficacy. Dr. Neil Singla, Chief Scientific Officer of Lotus Clinical Research will discuss these endpoints and criteria for submission of opioid-sparing labels to the FDA at the 11th Annual Pain and Migraine Therapeutics Summit, taking place in San Diego, CA on September 27-28, 2017. For more information, please visit: http://paintherapeuticsummit.com/brochure.

Dr. Singla will outline the regulatory criteria required when seeking an opioid-sparing claim on drug labels. He will provide examples of recently approved drugs for which opioid-sparing claims were sought, both successfully and unsuccessfully. He will also review labels, protocol designs and endpoints, and resulting publications for these drugs. Lastly, he will elaborate on the types of opioid-sparing labels the FDA awards.

Lotus Clinical Research, a specialty analgesic CRO and research site, has performed more than 100 analgesic clinical trials, as well as guided several analgesic agents through FDA approval. Dr. Singla’s expertise will provide attendees of the conference will an informative overview of maneuvering these labels. For more information on the services provided by Lotus Clinical Research, please visit: http://www.lotuscr.com/.

This annual conference provides a discussion platform for key industry and academic research leaders to network and deliberate many themes, including cutting-edge drug discovery science, preclinical development trends, analysis of novel clinical-stage pain therapies and newly marketed products. We will highlight the field’s most important developments in recent years, including: Nav 1.7 sodium channel blocker research, safer opioid analgesics, anti-CGRP receptor monoclonal antibodies, abuse-deterrent opioid development and more.

Please visit http://www.paintherapeuticsummit.com/agenda for the full agenda, which also includes numerous presentations covering clinical trial design and endpoints, regulatory and commercial issues, tools and technologies supporting pain drug discovery, and new scientific discoveries.

For more information, contact:
John Waslif: Managing Director
Arrowhead Publishers
866-945-0263 ext 700
john.waslif(at)arrowheadpublishers(dot)com

Rachel Donlon: Marketing Associate
Arrowhead Publishers
866-945-0263 ext 701
rachel.donlon(at)arrowheadpublishers(dot)com

Read the full story at http://www.prweb.com/releases/2017/08/prweb14618097.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Lotus Bio-Technology Reveals Financial Position of Strategic Partner, as Relationship Strengthens with the Creation of New CBD Product Line
2. Successful FDA Inspection at AXIS Clinicals USA
3. The Conference Forum confirms agenda for the 4th annual Mobile in Clinical Trials event on September 6, 2017
4. DrugDev and SCRS Present Educational Webinar on How to Develop an Efficient and Compliant Clinical Trial Start-Up Process
5. Myoderm Adds Clinical Trial Supply Veteran to Business Development Team -- New UK Warehouse Operational and Increasing Drug Supply Volume
6. 7th Annual DPharm: Disruptive Innovations to Advance Clinical Trials Conference Confirms Program Line-up for September 7-8, 2017
7. Former VP of Clinical Pharmacology at Nektar Therapeutics, Michael A. Eldon, PhD, FCP, Joins NDA Partners as Expert Consultant
8. Litmus Health Announces Advisory Board as Real-Life Data Gain Traction in Clinical Trials
9. TrialKit™ Allows Researchers to Easily Employ Core Motion and HealthKit™ on iPhone® and Apple Watch® in Clinical Trials
10. Microscan To Demonstrate Advancements in Barcode and Machine Vision Technology at AACC Clinical Lab Expo 2017
11. BioTech Holdings Announces First Clinical Use of Microbiome Optimized Autologous Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking ... initiative announced today. The bold new look is part of a transformation to ... into a significant growth period. , It will also expand its service offering from ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):